Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 31 tags : Phase 3 save search
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
PSTX | $2.24 3.94% 21K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -20.44%
phase 1 car-t results trial phase 2 phase 3
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
ADIL | News | $1.73 -8.95% 140K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress
Published: 2021-08-31 (Crawled : 15:00) - beyondspringpharma.com
BYSI | $2.11 7.7K
|
Health Technology
|
| O: 0.25%
H: 19.31%
C: 13.2%
presentation lung cancer europe cancer phase 3 plinabulin
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2021-08-31 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.73 -8.95% 140K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data
Published: 2021-08-31 (Crawled : 12:00) - biospace.com/
BYSI | $2.11 7.7K
|
Health Technology
|
| O: 0.25%
H: 19.31%
C: 13.2%
presentation phase 3
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818
Published: 2021-08-31 (Crawled : 08:00) - prnewswire.com
IGMS | $7.145 5.85% 22K
|
Health Technology
|
| O: 0.37%
H: 1.35%
C: -2.63%
phase 1 approval phase 2 phase 3
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
SMFL | $5.35 22.99% 11M
|
Manufacturing
KULR | $0.5446 22.0% 6.8M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.